Bimatoprost , ≥99% , 155206-00-1

Synonym(s):
Bimatoprost

CAS NO.：155206-00-1

Empirical Formula: C25H37NO4

Molecular Weight: 415.57

MDL number: MFCD03411999

EINECS: 642-890-9

PRODUCT Properties

• Melting point: 66-68°C
• Boiling point: 629.8±55.0 °C(Predicted)
• Density: 1.145±0.06 g/cm3(Predicted)
• storage temp.: -20°C
• solubility: Chloroform (Slightly), Dichloromethane (Slightly), Methanol (Slightly)
• form: solid
• pka: 14.25±0.20(Predicted)
• color: White to Off-White
• BCS Class: 3
• Stability: Light Sensitive
• Cosmetics Ingredients Functions: EYELASH CONDITIONING
• InChIKey: AQOKCDNYWBIDND-FTOWTWDKSA-N
• SMILES: C(NCC)(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CC=C1
• CAS DataBase Reference: 155206-00-1(CAS DataBase Reference)

Description and Uses

Bimatoprost was first introduced in the US and Brazil as Lumigan, an ophthalmic solution (0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, a proven risk of glaucomatous visual field loss. Bitamoprost is a new agent belonging to the PGF_2α analog class of prostamides launched in this indication after latanoprost, the most efficaceous topical medication currently available. This synthetic fatty acid amide can be prepared by esterification of 17- phenyl-18,19,20-trinorprostaglandin F_2α followed by ethylamidation. Bimatoprost, as related prostamides, is devoid of typical activities associated with PGF2,, analogs; it exhibits a unique pharmacological profile in contracting the feline iris sphincter with an EC₅₀ of 34 nM without interacting with any known prostanoid receptors. Thus it mimics the action of endogenous prostamides on specific receptors that lower IOP by increasing aqueous humor outflow through both pressure-insensitive and pressure-sensitive pathways without reducing humor formation. In a 3-month controlled clinical trial of efficacy and safety in patients with elevated IOP, bimatoprost demonstrated lower mean intraocular pressures at every time point throughout the study, as well as a good tolerance and systemic safety profile compared to latanoprost.

17-phenyl trinor Prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide) is an F-series PG analog which has been approved for use as an ocular hypotensive drug. Investigations in our lab have shown that 17-phenyl trinor PGF2α ethyl amide is converted by an amidase enzymatic activity in the bovine and human cornea to yield the corresponding free acid, with a conversion rate of about 40 μg/g corneal tissue/24 hours. The free acid, 17-phenyl trinor PGF2α, is a potent FP receptor agonist. In human and animal models of glaucoma, FP receptor agonist activity corresponds very closely with intraocular hypotensive activity.[Cayman Chemical]

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Danger
• Hazard statements: H302-H360F
• Precautionary statements: P201-P301+P312+P330-P308+P313
• PPE: Eyeshields, Gloves, type N95 (US)
• WGK Germany: 3
• Storage Class: 6.1C - Combustible acute toxic Cat.3; toxic compounds or compounds which causing chronic effects
• Hazard Classifications: Acute Tox. 4 Oral; Repr. 1B